Skip to content
HowShorted

Viking Therapeutics, Inc. short interest in 2023

In 2023, Viking Therapeutics, Inc.'s disclosed short interest ran from 5.05% of shares outstanding on 31 Jan 2023 to 13.45% on 29 Dec 2023, a change of +8.40 percentage points. The year's high was 16.96% on 15 Nov 2023 and its low 5.05% on 31 Jan 2023, averaging 12.24% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.63 days on 31 Aug 2023. Full history: Viking Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Viking Therapeutics, Inc. in 2023

2023 in figures

Start of year
5.05% (31 Jan 2023)
End of year
13.45% (29 Dec 2023)
Change
+8.40 pp
High
16.96% (15 Nov 2023)
Low
5.05% (31 Jan 2023)
Average
12.24%
Highest days to cover
11.63 (31 Aug 2023)
SEC filings marked
8

Every report in 2023

Viking Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
31 Jan 20235.05%3.07
15 Feb 20235.95%2.26results (8-K), 10-K filed
28 Feb 20236.18%2.64
15 Mar 20236.77%3.27
31 Mar 202314.35%1.00
14 Apr 202314.59%3.00
28 Apr 202311.64%2.7710-Q filed, results (8-K)
15 May 202312.08%4.96
31 May 202311.94%2.96
15 Jun 202311.11%5.95
30 Jun 202312.14%2.10
14 Jul 202312.22%7.20
31 Jul 202311.84%6.6610-Q filed, results (8-K)
15 Aug 202313.58%7.43
31 Aug 202312.91%11.63
15 Sep 202313.63%6.26
29 Sep 202313.89%6.06
13 Oct 202314.80%7.31
31 Oct 202316.41%6.9510-Q filed, results (8-K)
15 Nov 202316.96%9.22
30 Nov 202315.42%11.34
15 Dec 202314.60%3.19
29 Dec 202313.45%5.85

See also: Viking Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.